Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOCRYST PHARMACEUTICALS INC Director's Dealing 2019

Nov 18, 2019

31868_dirs_2019-11-18_b2f449d6-1d41-4cd6-bb79-4a9f5f134561.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2019-11-18

Reporting Person: Babu Yarlagadda S (Senior VP - Drug Discovery)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2019-11-18 Common Stock P 25000 $1.45 Acquired 155587 Direct